The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial

Karsai, Syrus; Friedl, Hannah; Buhck, Hartmut; Jünger, Michael; Podda, Maurizio

doi:10.1111/bjd.13266

Cited by 29 publications

(15 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When comparing recurrence of low‐risk BCC post‐treatment with either PDL‐PDT or PDT alone, Carija et al found a higher recurrence rate in the combination arm which they postulated could be secondary to a reduction in photobleaching in PDL‐treated skin . A double‐blind randomized placebo‐controlled trial comparing PDL to placebo found a 78.6% complete remission in the PDL group, with a significant superiority demonstrated against placebo ( P < 0.0001).They did however note that pigmentary scarring was noted to be a limitation of this treatment . While there is evidence of PDL in some BCCs; current practice relates largely to small well‐defined superficial and/or nodular BCCs in low‐risk areas.…”

Section: Basal Cell Carcinomamentioning

confidence: 99%

Nonvascular uses of pulsed dye laser in clinical dermatology

Forbat

Al‐Niaimi

2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Lasers are fast becoming the vogue of dermatology ranging from ablative, nonablative, fractional photothermolysis to vascular lasers. There are a range of vascular lasers including potassium titanyl phosphate (KTP 532 nm), pulsed dye laser (PDL −595 nm), diode (810 nm), and Nd:YAG (1064 nm). PDL is a laser that emits yellow light using Rhodamine dye as it is lasing medium. Typical vascular lesions which are treated by PDL include port wine stain, hemangioma, telangiectasia, spider angioma, and rosacea. This article focuses on the use of PDL beyond primary vascular conditions. We review the evidence, or lack thereof, of the use of PDL in acne vulgaris, scars, striae, warts, molluscum, psoriasis, rejuvenation, basal cell carcinoma (BCC), and miscellaneous dermatological sequelae. K E Y W O R D Sacne, laser, nonvascular, psoriasis, pulsed dye, scar

show abstract

Section: Basal Cell Carcinomamentioning

confidence: 99%

Nonvascular uses of pulsed dye laser in clinical dermatology

Forbat

Al‐Niaimi

2019

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…A 2015 study examined dye laser therapy prospectively. Tumor clearance was achieved in 78 % of sBCCs at low‐risk sites; however, there was frequent dyspigmentation . Clinical data is also available for the Nd:YAG laser (1,064 nm).…”

Section: Topical Treatmentmentioning

confidence: 99%

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

Lang

Balermpas

Bauer

et al. 2019

J Deutsche Derma Gesell

125

View full text Add to dashboard Cite

SummaryBasal cell carcinoma (BCC) is the most common malignant tumor among fair‐skinned individuals, and its incidence had been steadily rising in the past decades. In order to maintain the highest quality of patient care possible, the German S2k guidelines were updated following a systematic literature search and with the participation of all professional societies and associations involved in the management of the disease. Part 2 addresses issues such as proper risk stratification, the various therapeutic approaches, and prevention as well as follow‐up of patients with basal cell carcinoma.

show abstract

“…In einer 2015 veröffentlichten Studie wurde der Einsatz eines Farbstofflasers prospektiv untersucht. Hier konnten bei sBZK in Niedrigrisiko‐Lokalisationen in 78 % eine Tumorfreiheit erreicht werden, jedoch kam es regelmäßig zu Pigmentverschiebungen . Auch zum 1064 nm Nd:YAG‐Laser liegen klinische Daten vor.…”

Section: Topische Therapieunclassified

S2k‐Leitlinie Basalzellkarzinom der Haut – Teil 2: Therapie, Prävention und Nachsorge

Lang

Balermpas²,

Bauer

et al. 2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Das Basalzellkarzinom (BZK) ist der häufigste maligne Tumor der hellhäutigen Bevölkerung mit jährlich steigender Inzidenz. Eine Aktualisierung der S2k‐Leitlinie unter Beteiligung aller mit dem Krankheitsbild vertrauten Fachgesellschaften sowie vorangegangener Literaturrecherche ist für die Qualität der Versorgung der betroffenen Patienten von essentieller Bedeutung. Im vorliegenden Teil 2 wird zunächst eine Risikostratifizierung aufgezeigt, bevor die verschiedenen Therapieoptionen diskutiert werden. Zudem werden Prävention und Nachsorge der Erkrankung behandelt.

show abstract

The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial

Abstract: PDL is an effective and safe method for treating sBCC. However, the occurrence of persistent dyspigmentation still limits the potential for excellent cosmetic outcomes.

Cited by 29 publications

References 22 publications

Nonvascular uses of pulsed dye laser in clinical dermatology

Nonvascular uses of pulsed dye laser in clinical dermatology

S2k Guidelines for Cutaneous Basal Cell Carcinoma – Part 2: Treatment, Prevention and Follow‐up

S2k‐Leitlinie Basalzellkarzinom der Haut – Teil 2: Therapie, Prävention und Nachsorge

Contact Info

Product

Resources

About